http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0217968-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b400a6b9feb9869e9d5649b7d2a0430 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2001-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b6d9ae68dda4c8588b5c29be4a9698a |
| publicationDate | 2002-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0217968-A9 |
| titleOfInvention | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| abstract | The invention relates to the discovery that cancer cells that have no or low expression of the IL-13 receptor ('IL-13R') can bind IL-13R-targeted immunoconjugates, such as immunotoxins, by transfection with the IL-13Rα2 chain alone. Transfecting cells with just the IL-13Rα2 chain is easier than transfection with an intact receptor. For some cancers, transfection with the IL-13Rα2 chain alone inhibits tumor growth. Those cancers that are not inhibited by the presence of the IL-13Rα2 chain alone, and which do not express the IL-13R or express it only at low levels can be rendered sensitive to IL-13R-targeted immunoconjugates by transfection of the IL-13α2 chain and can be inhibited by the use of immunoconjugates, such as immunotoxins, targeted to the IL-13R. Nucleic acids encoding the IL-13Rα2 chain or vectors containing such nucleic acids can be used for the manufacture of medicaments to introduce the IL-13Rα2 chain into cancer cells and thereby either inhibit their growth (for cells inhibited by the presence of the IL-13Rα2 chain) or to sensitize them to IL-13R-targeted immunoconjugates, or both. |
| priorityDate | 2000-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 657.